Aveo, Lilly Partner to Evaluate Ficlatuzumab and Cetuximab in head, neck carcinoma

 This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada -

- AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 -

https://finance.yahoo.com/news/aveo-oncology-announces-clinical-trial-120000607.html